Pacific Biosciences
PACB
225 hedge funds and large institutions have $266M invested in Pacific Biosciences in 2025 Q1 according to their latest regulatory filings, with 36 funds opening new positions, 57 increasing their positions, 74 reducing their positions, and 35 closing their positions.
148% more call options, than puts
Call options by funds: $4.29M | Put options by funds: $1.73M
3% more first-time investments, than exits
New positions opened: 36 | Existing positions closed: 35
0% more funds holding in top 10
Funds holding in top 10: 2 → 2 (0)
0% less funds holding
Funds holding: 226 → 225 (-1)
19.17% less ownership
Funds ownership: 94.77% → 75.6% (-19%)
23% less repeat investments, than reductions
Existing positions increased: 57 | Existing positions reduced: 74
44% less capital invested
Capital invested by funds: $475M → $266M (-$210M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Vanguard Group
Malvern,
Pennsylvania
|
+$1.59M |
| 2 |
KOC
Koss-Olinger Consulting
Gainesville,
Florida
|
+$1.53M |
| 3 |
UBS Group
Zurich,
Switzerland
|
+$1.22M |
| 4 |
EDRH
Edmond de Rothschild Holding
Chambesy,
Switzerland
|
+$780K |
| 5 |
XT
XTX Topco
George Town,
Cayman Islands
|
+$749K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Millennium Management
New York
|
-$22.8M |
| 2 |
Bank of New York Mellon
New York
|
-$6.66M |
| 3 |
Goldman Sachs
New York
|
-$4.49M |
| 4 |
Walleye Capital
New York
|
-$3.56M |
| 5 |
Morgan Stanley
New York
|
-$3.5M |
| Name | Holding | Trade Value |
Shares Change |
Change in Stake |
|
|---|---|---|---|---|---|
251
AssetMark Inc
Concord,
California
| – | -$915 | -500 | Closed |
|
|
GI
252
GAMMA Investing
Foster City,
California
| – | -$558 | -305 | Closed |
|
|
CA
253
CoreCap Advisors
Southfield,
Michigan
| – | -$514 | -281 | Closed |
|
|
MRP
254
Measured Risk Portfolios
San Diego,
California
| – | -$441 | -241 | Closed |
|
|
MCM
255
MAI Capital Management
Independence,
Ohio
| – | -$280 | -153 | Closed |
|
|
OP
256
ORG Partners
Roanoke,
Indiana
| – | -$184 | -101 | Closed |
|
257
Northwestern Mutual Wealth Management
Milwaukee,
Wisconsin
| – | -$37 | -20 | Closed |
|
|
AW
258
Avion Wealth
The Woodlands,
Texas
| – | +$502 | +327 | New |
|
PACB Hedge Fund Activity: Q1 2025 in Review
225 of the 7,457 institutional investors tracked by Wall St. Rank reported a position in Pacific Biosciences (PACB) for Q1 2025, worth a combined $266M — down 44% from $475M a quarter earlier.
Buyers outnumbered sellers: 36 funds opened new PACB positions and 35 closed out — a net gain of 1 holder — while 57 added to existing stakes and 74 trimmed.
The largest buyer was Vanguard Group, adding an estimated $1.59M. The largest seller was Millennium Management, cutting an estimated $22.8M.
- 225 institutional investors held Pacific Biosciences (PACB) as of Q1 2025, down from 226 in Q4 2024.
- Funds reported $266M of Pacific Biosciences stock for Q1 2025, down 44% quarter-over-quarter.
- 36 funds opened new Pacific Biosciences positions in Q1 2025 and 35 closed out, a net change of +1 holder.
- The largest Pacific Biosciences buyer in Q1 2025 was Vanguard Group, an estimated $1.59M added.
- The largest Pacific Biosciences seller in Q1 2025 was Millennium Management, an estimated $22.8M sold.
Based on aggregated 13F filings for Q1 2025.